Aerie Pharmaceuticals, Inc.

NasdaqGM:AERI Stock Report

Market Cap: US$753.6m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Aerie Pharmaceuticals Future Growth

Future criteria checks 4/6

Key information

67.5%

Earnings growth rate

78.2%

EPS growth rate

Pharmaceuticals earnings growth17.2%
Revenue growth rate19.3%
Future return on equityn/a
Analyst coverage

Good

Last updatedn/a

Recent future growth updates

Recent updates

Alcon to acquire Aerie Pharmaceuticals at ~$770M, enhancing its ophthalmic pharmaceutical portfolio

Aug 23

Aerie Pharmaceuticals grants 16.9K stock options

Aug 15

Aerie Pharma rises 14% after Q2 result beat on higher glaucoma franchise sales

Aug 05

Aerie Pharma completes enrollment in first Phase 3 trial of netarsudil in Japan

Jun 17

Aerie Pharmaceuticals, Inc.'s (NASDAQ:AERI) Path To Profitability

Feb 27
Aerie Pharmaceuticals, Inc.'s (NASDAQ:AERI) Path To Profitability

Who Has Been Selling Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Shares?

Jan 28
Who Has Been Selling Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Shares?

Aerie Pharmaceuticals receives European approval for Roclanda

Jan 11

Aerie Pharmaceuticals (NASDAQ:AERI) Share Prices Have Dropped 76% In The Last Three Years

Dec 24
Aerie Pharmaceuticals (NASDAQ:AERI) Share Prices Have Dropped 76% In The Last Three Years

Is Aerie Pharmaceuticals (NASDAQ:AERI) A Risky Investment?

Nov 28
Is Aerie Pharmaceuticals (NASDAQ:AERI) A Risky Investment?

European advisory group backs Aerie Pharma's Roclanda

Nov 13

Earnings and Revenue Growth Forecasts

NasdaqGM:AERI - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2024226-26-2418
12/31/2023180-64-56610
12/31/2022138-123-89-15
9/30/2022214-3737N/A
6/30/2022207-49-50N/A
3/31/2022201-69-11-7N/A
12/31/2021194-75-102-99N/A
9/30/2021104-166-50-47N/A
6/30/202195-166-53-50N/A
3/31/202186-176-56-53N/A
12/31/202083-183-68-65N/A
9/30/202083-192-127-114N/A
6/30/202082-202-142-130N/A
3/31/202079-201-158-144N/A
12/31/201970-200-168-150N/A
9/30/201960-196-165-155N/A
6/30/201948-232-175-160N/A
3/31/201935-240-188-160N/A
12/31/201824-233-184-153N/A
9/30/201810-240-196-147N/A
6/30/20182-187-172-125N/A
3/31/2018N/A-160-144-109N/A
12/31/2017N/A-145-120-93N/A
9/30/2017N/A-116-97-86N/A
6/30/2017N/A-107-93-86N/A
3/31/2017N/A-102-91-85N/A
12/31/2016N/A-99-85-80N/A
9/30/2016N/A-90-78-75N/A
6/30/2016N/A-84N/A-66N/A
3/31/2016N/A-80N/A-62N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AERI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: AERI is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: AERI is expected to become profitable in the next 3 years.

Revenue vs Market: AERI's revenue (19.3% per year) is forecast to grow faster than the US market (6.9% per year).

High Growth Revenue: AERI's revenue (19.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if AERI's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/11/21 21:52
End of Day Share Price 2022/11/18 00:00
Earnings2022/09/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aerie Pharmaceuticals, Inc. is covered by 17 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason Matthew GerberryBofA Global Research
Difei YangBrean Capital
John NewmanCanaccord Genuity